Non-Alcoholic Fatty Liver Disease Market Overview

The global Non-Alcoholic Fatty Liver Disease market is estimated to be worth over USD 13.95Bn in 2033 and is expected to grow at CAGR of24.18% during the forecast period (2024-2033).

Non-alcoholic fatty liver disease (NAFLD) is a common and potentially severe condition characterized by the collection of fat in the liver cells of individuals who consume little to no alcohol. NAFLD encompasses a spectrum of liver disorders, ranging from simple steatosis (accumulation of fat) to non-alcoholic steatohepatitis (NASH), which includes inflammation, liver cell damage, and likely to progress to fibrosis, cirrhosis, and even hepatocellular carcinoma (liver cancer). NAFLD is nearly associated with metabolic risk factors such as type 2 diabetes, obesity, dyslipidemia, and insulin resistance, making it a substantial public health concern across the world.

The global market for NAFLD is experiencing considerable growth owing to the increasing prevalence of obesity and metabolic disorders, along with greater awareness and diagnosis rates. Diagnostic tests such as imaging techniques (MRI, ultrasound) and blood tests (liver function tests, lipid profile) hold a critical role in determining NAFLD patients and evaluating disease intensity. However, challenges persist in meticulously diagnosing and monitoring NAFLD progression, specifically distinguishing between simple steatosis and NASH. As a consequence, there is a soaring demand for non-invasive diagnostic methods and biomarkers to support early detection and risk stratification.

In terms of therapeutics, lifestyle modifications including dietary changes and exercise remain the foundation of NAFLD management. Pharmacotherapy options for NAFLD/NASH are limited, with no approved drugs specifically targeting the underlying pathology. However, there is a favourable pipeline of investigational drugs targeting various pathways implicated in NAFLD pathogenesis, including metabolic, inflammatory, and fibrotic pathways. The soaring focus on developing effective pharmacotherapies for NAFLD/NASH presents significant opportunities for pharmaceutical companies and biotech firms.

Geographically, North America and Europe currently dominate the NAFLD market attributing to the increased prevalence of obesity and metabolic syndrome in these regions, coupled with advanced healthcare infrastructure and research initiatives. However, the Asia Pacific region is expected to witness rapid growth driven by the growing incidence of NAFLD/NASH in countries experiencing rapid urbanization and lifestyle changes.

Overall, the global market for NAFLD represents both challenges and opportunities for stakeholders, comprising healthcare providers, pharmaceutical companies, diagnostic manufacturers, and research institutions, as they strive to address the unmet needs of patients and enhance outcomes in this increasingly prevalent and complex liver disorder.

Figure 1. Non-Alcoholic Fatty Liver Disease: Market Size

Get more details on this report - Request Free Sample

Key Market Insights &Current Market Landscape:

The global non-alcoholic fatty liver disease (NAFLD) market is experiencingremarkable growth and evolution fuelled by numerous key market insights and developments. The surging prevalence of type 2 diabetes, obesity, and metabolic syndrome across the world has led to an higher incidence of NAFLD, making it one of the most common liver diseases worldwide. Consequently, there is a soaring focus on early diagnosis and effective management strategies for NAFLD patients.

In the current market landscape, diagnostic tests holds an integral role in identifying and monitoring NAFLD patients. Imaging techniques such as ultrasound, MRI, and CT scans are generally used for liver fat quantification and assessment of fibrosis. In addition, blood tests including liver function tests, lipid profile, and biomarkers such as serum markers of fibrosis are employed for disease evaluation. However, there is a growing demand for non-invasive diagnostic methods and innovative biomarkers to enhance diagnostic accuracy and promote risk stratification, particularly in distinguishing between simple steatosis and NASH.

On the therapeutic front, lifestyle modifications including dietary changes and exercise remain the primary treatment approach for NAFLD patients. However, there is a notable lack of approved pharmacotherapies specifically targeting NAFLD/NASH. However, the market is witnessing significant developments with a promising pipeline of investigational drugs targeting various pathways implicated in NAFLD pathogenesis, including metabolic, inflammatory, and fibrotic pathways. Emerging novel technologies such as RNA interference (RNAi) therapeutics, monoclonal antibodies, and gene editing techniques provide potential avenues for developing effective pharmacotherapies for NAFLD/NASH.

Overall, the global NAFLD market represents opportunities for innovation and growth as stakeholders continue to address the unmet needs of patients and strive to enhance outcomes in this complex and multifaceted liver disorder.

Market Dynamics

Market Drivers

Increase in the NASH-affected population

NASH represents the more acute end of the NAFLD spectrum, marked by inflammation and liver cell damage, which can progress to advanced liver fibrosis, cirrhosis, and hepatocellular carcinoma (liver cancer). Since the prevalence of obesity, type 2 diabetes, and metabolic syndrome remains to surge globally, so does the incidence of NASH, making it a growing public health concern. This escalating burden of NASH drives the demand for diagnostic tests, therapeutic interventions, and innovative treatment approaches within the NAFLD market. Healthcare providers, pharmaceutical firms, and diagnostic manufacturers are increasingly emphasizing their efforts on addressing the unmet needs of NASH patients, including accurate diagnosis, disease monitoring, and effective management strategies. In addition to that, the expanding NASH-affected population presents opportunities for research and development of novel pharmacotherapies targeting NASH-specific pathways, fueling innovation and investment in the NAFLD market to enhance patient outcomes and mitigate the burden of this progressive liver disease.

Market Restraints

With regard to numerous advantages of Non-Alcoholic Fatty Liver Disease, the market faces several challenges due to the unique characteristics and requirements associated with them. Some of the key market challenges include:

1. Limited Treatment Options: The absence of approved pharmacotherapies specifically targeting non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) represents a significant market restraint. Regardless of the growing prevalence of NAFLD/NASH, there are currently no FDA-approved drugs for the treatment of these conditions. This limitation restricts the options available for healthcare providers and patients, resulting into a reliance on lifestyle modifications and off-label use of medications targeting related metabolic conditions.
2. Diagnostic Challenges: The intricacy of diagnosing and monitoring NAFLD/NASH represents a significant market restraint. Whilst various diagnostic tests are available, comprising imaging techniques and blood biomarkers, precisely distinguishing between simple steatosis and NASH remains arduous. Liver biopsy, considered the gold standard for NASH diagnosis, is invasive and associated with risks, paving its way to a hesitation among patients and healthcare providers. Additionally, the lack of standardized diagnostic criteria and the variability in disease presentation further complicate accurate diagnosis and disease management, hindering market growth and impeding patient care.

Get more details on this report - Request Free Sample

Market Opportunities

Development of Novel Therapies with Minimum Side Effects

With the growing prevalence of NAFLD/NASH and the absence of FDA-approved pharmacotherapies particularly targeting these conditions, there is a soaring demand for advanced diagnostic tools and therapeutic interventions. Investment in R&D efforts emphasized at developing novel drugs, diagnostic tests, and treatment modalities provides potential solutions to address the unmet needs of NAFLD/NASH patients. Emerging technologies such as RNA interference (RNAi) therapeutics, monoclonal antibodies, and gene editing techniques hold commitment for targeting key pathways implicated in NAFLD pathogenesis. In addition, advancements in non-invasive diagnostic methods and biomarkers facilitate early detection, disease monitoring, and risk stratification, enhancing patient care and treatment outcomes. The expanding pipeline of investigational drugs and diagnostic innovations reflects a growing commitment from pharmaceutical firms, biotech companies, and research institutions to address the complexities of NAFLD/NASH, fueling market growth and positioning the industry to meet the evolving needs of patients and healthcare providers.

Market Trends

1. Increasing Focus on Precision Medicine: There is a soaring trend towards personalized or precision medicine within the global non-alcoholic fatty liver disease (NAFLD) market. This trend comprises tailoring treatment strategies on the basis of individual patient characteristics, such as genetic predisposition, metabolic profile, and disease severity. Breakthroughs in molecular diagnostics, biomarker discovery, and genetic testing enable healthcare providers to better understand the underlying mechanisms of NAFLD/NASH and identify patient subgroups that are likely to respond differently to particular therapies. Precision medicine approaches hold the potential to improve treatment efficacy, minimize side effects, and optimize healthcare resource utilization, encouraging adoption and investment in personalized therapeutic interventions for NAFLD/NASH.
2. Rising Adoption of Digital Health Solutions: The global NAFLD market is experiencing an increasing adoption of digital health solutions focused at improving patient engagement, disease management, and healthcare delivery. Wearable devices, mobile applications, and telemedicine platforms presents opportunities for remote monitoring, lifestyle coaching, and medication adherence support for NAFLD patients. These digital health tools allow real-time data collection, analysis, and feedback, empowering patients to take an active role in managing their health and support communication between patients and healthcare providers. In addition, digital health solutions streamline clinical workflows, improve access to care, and reduce healthcare costs, encouraging their integration into routine clinical practice and defining the future of NAFLD management.

Get more details on this report - Request Free Sample

Non-Alcoholic Fatty Liver Disease Market: Key Segments

By Drug Type

• Vitamin E and Pioglitazone
• Ocaliva
• Elafibranor
• Elonsertib and Cenicriviroc
• Obeticholic Acid
• Others

By Sales Channel

• Hospital Pharmacy
• Online Providers
• Retail Pharmacy

By Disease Cause

• Hypertension
• Heart Disease
• High Blood Lipid
• Type 2 Diabetes
• Obesity

By End User

• Hospitals
• Clinics
• Homecare Settings

By Key Geographical Regions

• North America
• Europe
• Asia-Pacific
• Middle East and Africa
• South America 

Non-Alcoholic Fatty Liver Disease Market: Regional Analysis

Asia Pacific dominates the non-alcoholic steatohepatitis market due to the diagnostic techniques. Furthermore, the increase in the incidences of non-alcoholic steatohepatitis (NASH) and the development in the economies will further boost the growth of the non-alcoholic steatohepatitis market in the region during the forecast period. North America is projected to observe significant amount of growth in the non-alcoholic steatohepatitis market due to the increase in the incidences of obese patients. Moreover, the rise in the cases of non-alcoholic fatty liver disease is further anticipated to propel the growth of the non-alcoholic steatohepatitis market in the region in the coming years.

Figure 4. Non-Alcoholic Fatty Liver Disease Market: Distribution by Region

Get more details on this report - Request Free Sample

Leading Non-Alcoholic Fatty Liver Disease Developers

Industry Trends and Global Forecasts, 2023-2035 report features an extensive study of the current market landscape, market size and future opportunities associated with the Non-Alcoholic Fatty Liver Disease market, during the given forecast period. Further, the market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the biopharmaceutical industry. Key takeaways of the Non-Alcoholic Fatty Liver Disease market are briefly discussed below. 

The report includes the list of players operating in the global Non-Alcoholic Fatty Liver Disease market. Some of the key players include: 

• AbbVie Inc.
• Algernon Pharmaceuticals
• Allergan plc
• Boehringer Ingelheim International GmbH.
• Bristol Myers Squibb Company
• Celerion
• Conatus Pharmaceuticals Inc.
• Enzo Biochem Inc.
• Galmed Pharmaceuticals Ltd
• Gemphire
• Genfit SA
• Gilead Sciences, Inc.
• Immuron
• Intercept Pharmaceuticals, Inc.
• Novartis AG
• NuSirt Biopharma
• Novo Nordisk A/S
• Pfizer Inc.
• Perspectum Diagnostics
• Shire
• Zydus Pharmaceuticals, Inc

Recent Developments in the Non-Alcoholic Fatty Liver Disease Market

Several recent developments have taken place in the field of Non-Alcoholic Fatty Liver Disease, some of which have been outlined below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that we’ve outlined in our analysis chronologically.

• In March 2024, the U.S. Food and Drug Administration approved Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), to be used along with diet and exercise. 

Scope of the Report

The market report presents an in-depth analysis of the various firms / organizations that are engaged in this market, across different segments, as defined in the below table: